Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
– Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer –
– Tecentriq and nab-paclitaxel significantly reduced the risk of disease worsening or death in both the intention-to-treat and PD-L1-positive populations –
– Clinically meaningful overall survival improvement in the PD-L1-positive population at this interim analysis –
– Data are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress, featured in the press program and simultaneously published in the New England Journal of Medicine on October 20, 2018 –
